Launched first generic 'COVIFOR' (Remdesivir) in India for the treatment of COVID-19 (licensing agreement with Gilead Sciences Inc.)

Basic manufacturer of Oseltamivir (sub-licensing agreement with Hoffman-La Rosche, Switzerland).

Launched first generic Bictegravir combination therapy in India under the brand name 'TAFFIC'.

Launched 'TAFERO-EM', first generic fixed-dose combination of 'Emtricitabine and Tenofovir Alafenamide' in India.

Launched biosimilar Rituximab for the treatment of chronic leukaemia.

Won "Express Pharma Excellence Award for COVID-19 drug launch" rewarding our contribution to provide COVIFOR(Remdesivir) access to more than 1 lakh patients.

Won "Certificate of Excellence" Gold Award for ITBOR from AWACS under new introductions of "ACUTE" category amongst the top 21-50 companies for 2019.